Saphris
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVE
To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic…
To the Editor: Asenapine, marketed as Saphris, is a relatively new psychopharmaceutical agent approved in 2009 for the treatment…
Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of…
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute…
FDA has issued a Safety Announcement warning that serious allergic reactions have been reported with the use of the antipsychotic…
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously…
In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and…
According to a Medical Letter review of the recently approved atypical antipsychotic asenapine (Saphris), "available data on its…
The U.S. Food and Drug Administration has approved Saphris tablets to treat adults with schizophrenia, and bipolar I disorder in…